**Hey @Aktienhauptmeister,**
Awesome pitch—I’ve got to give you credit for that! You sold the story of the “chef in the biotech lab” brilliantly—it almost makes you want to click “Buy” right away. But let’s set aside the emotions and the nice story for a moment and lay the raw numbers out on the dissection table. Because your “Next Big Thing” is failing my quality control test absolutely and mercilessly. 😉
Here are the areas where your story falls apart:
* **The “hyper-growth lever” is a drop in the bucket:**
You’re touting the *Clinical Solutions* segment for a staggering 85% growth. Great in percentage terms, but let’s look at the absolute numbers: Revenue here rose from $1.2 million to $2.1 million in Q1. That’s minuscule at the corporate level. If just a single customer’s clinical trial falters or gets delayed, that percentage growth story will immediately collapse.
* **The Margin Illusion:**
You call the 34.2% gross margin the crown jewel. But what good is the most impressive gross margin if operating expenses (OpEx) are crushing the company? The $8.1 million in operating expenses completely wiped out the $3.8 million gross profit in the first quarter. The bottom line is an operating loss of $4.3 million. We’re talking about a net profit margin of around **-41%**!
* **The ticking cash clock (my biggest headache):**
Yes, $17.8 million in cash on hand sounds okay, but the bottom line is that the money keeps burning through at a rapid pace. Management hopes to be profitable on an adjusted EBITDA basis by *the end of 2027*. For a micro-cap, that’s an eternity. If the sector stumbles for just one quarter, the company will run out of money right before the finish line. We all know what comes next: a massive capital increase and brutal dilution for everyone currently invested.
**My conclusion based on my rules:**
You know my strict quality formula. Let’s quickly run the numbers: 13% revenue growth + (-38.7%) operating margin = **a score of -25.7**.
My target range for “solid” is 15 to 25. At -25.7, my most important exclusion rule kicks in: No purchases if the operating margin is consistently deep in the red and the narrative is significantly bigger than the actual numbers.
That might be exciting for a gamble, but for a portfolio designed for substance and quality, it’s nothing more than a lottery ticket. I’d rather stay relaxed on the sidelines and see if your head chef ever starts making real money! 😎
Awesome pitch—I’ve got to give you credit for that! You sold the story of the “chef in the biotech lab” brilliantly—it almost makes you want to click “Buy” right away. But let’s set aside the emotions and the nice story for a moment and lay the raw numbers out on the dissection table. Because your “Next Big Thing” is failing my quality control test absolutely and mercilessly. 😉
Here are the areas where your story falls apart:
* **The “hyper-growth lever” is a drop in the bucket:**
You’re touting the *Clinical Solutions* segment for a staggering 85% growth. Great in percentage terms, but let’s look at the absolute numbers: Revenue here rose from $1.2 million to $2.1 million in Q1. That’s minuscule at the corporate level. If just a single customer’s clinical trial falters or gets delayed, that percentage growth story will immediately collapse.
* **The Margin Illusion:**
You call the 34.2% gross margin the crown jewel. But what good is the most impressive gross margin if operating expenses (OpEx) are crushing the company? The $8.1 million in operating expenses completely wiped out the $3.8 million gross profit in the first quarter. The bottom line is an operating loss of $4.3 million. We’re talking about a net profit margin of around **-41%**!
* **The ticking cash clock (my biggest headache):**
Yes, $17.8 million in cash on hand sounds okay, but the bottom line is that the money keeps burning through at a rapid pace. Management hopes to be profitable on an adjusted EBITDA basis by *the end of 2027*. For a micro-cap, that’s an eternity. If the sector stumbles for just one quarter, the company will run out of money right before the finish line. We all know what comes next: a massive capital increase and brutal dilution for everyone currently invested.
**My conclusion based on my rules:**
You know my strict quality formula. Let’s quickly run the numbers: 13% revenue growth + (-38.7%) operating margin = **a score of -25.7**.
My target range for “solid” is 15 to 25. At -25.7, my most important exclusion rule kicks in: No purchases if the operating margin is consistently deep in the red and the narrative is significantly bigger than the actual numbers.
That might be exciting for a gamble, but for a portfolio designed for substance and quality, it’s nothing more than a lottery ticket. I’d rather stay relaxed on the sidelines and see if your head chef ever starts making real money! 😎
•
77
•
@Raketentoni It’s not exactly something for my portfolio😂—more like something for the speculator’s corner, with that typical small-cap risk, and as you know, I’m completely out of that game 😂 But this wild price action since February has piqued my curiosity. 🤷🏼♂️ I don’t usually feature companies like this, but a little speculative adrenaline for a change can’t hurt 👀🤣
•
44
•
@Aktienhauptmeister I think it's great that you're sharing these risk metrics here, even though they don't really fit with your own philosophy.
•
11
•@Multibagger For you, anyway 😆 It can't hurt to come up with numbers like that every now and then 😬 Maybe you'll get something out of it, too 😏
•
11
•